DOCSLIB.ORG

Compendial Deferrals for USP41-NF36 1S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Compendial Deferrals for USP41-NF36 1S Compendial Deferrals for USP41-NF36 1S Category Monograph Title Monograph Section Scientific Liaison {Emollient} Sodium Lauroyl Sarcosinate, {Emulsifying Agent} Sodium Lauroyl Revision USP AND NF EXCIPIENTS, LISTED BY CATEGORY PF 42(2) Pg. ONLINE Sarcosinate, {Chaotropic Agent} Hong Wang Introduction, 1. INTRODUCTION, 2. GENERAL QUALITY TESTS FOR INHALATION DRUG <5> INHALATION AND NASAL DRUG PRODUCTS GENERAL INFORMATION AND PRODUCTS, 3. GENERAL QUALITY TESTS FOR NASAL DRUG PRODUCTS, 4. Revision PRODUCT QUALITY TESTS PF 43(1) Pg. ONLINE DESCRIPTION OF PRODUCT QUALITY TESTS Kahkashan Zaidi Bendamustine Hydrochloride, Ropivacaine, Bortezomib, Sodium Lauroyl Sarcosinate, Epinastine Hydrochloride, Imipramine Hydrochloride, Carglumic Acid, Iloperidone, Benzphetamine Hydrochloride, Deferasirox, Eletriptan Hydrobromide, Milnacipran New DESCRIPTION AND SOLUBILITY PF 43(1) Pg. ONLINE Hydrochloride, Nebivolol Hydrochloride Feiwen Mao Title, INTRODUCTION/Introduction, PROCEDURE/Identification, PROCEDURE/Enumeration, PERFORMANCE TESTS/, CONTAMINANTS/Introduction, CONTAMINANTS/Listeria, ADDITIONAL REQUIREMENTS/Storage, ADDITIONAL New <64> PROBIOTIC TESTS - GENERAL PF 43(2) Pg. ONLINE REQUIREMENTS/Labeling, ??UNKNOWN??/Introduction Seong Jae Yoo Title, Introduction, INTRODUCTION, CHARACTERISTICS, IDENTIFICATION, TEST PROCEDURES, BIOLOGICAL TESTS, PHYSICOCHEMICAL TESTS, FUNCTIONALITY New <381> ELASTOMERIC CLOSURES FOR INJECTIONS PF 43(3) Pg. ONLINE TESTS, 1. INTRODUCTION, 2. SCOPE, 3. SPECIFICATIONS, 4. TEST METHODS Desmond Hunt Title, 1. INTRODUCTION, 2. SCOPE, 3. GENERAL TEST REQUIREMENTS, 4. PACKAGE <382> ELASTOMERIC CLOSURE FUNCTIONALITY IN INJECTABLE PHARMACEUTICAL INTEGRITY, 5. NEEDLE AND SPIKE ACCESS FUNCTIONALITY TESTS, 6. PLUNGER New PACKAGING/DELIVERY SYSTEMS PF 43(3) Pg. ONLINE FUNCTIONALITY TESTS, 7. TIP CAP AND NEEDLE SHIELD FUNCTIONALITY TESTS Desmond Hunt Introduction, INTRODUCTION, CLASSIFICATION OF RESIDUAL SOLVENTS BY RISK ASSESSMENT, METHODS FOR ESTABLISHING EXPOSURE LIMITS, OPTIONS FOR DESCRIBING LIMITS OF CLASS 2 RESIDUAL SOLVENTS, ANALYTICAL PROCEDURES, REPORTING LEVELS OF RESIDUAL SOLVENTS, LIMITS OF RESIDUAL SOLVENTS, IDENTIFICATION, CONTROL, AND QUANTIFICATION OF RESIDUAL SOLVENTS, GLOSSARY, APPENDIX 1. LIST, APPENDIX 2. ADDITIONAL BACKGROUND, APPENDIX 3. PROCEDURES FOR ESTABLISHING EXPOSURE LIMITS, 1. INTRODUCTION, 2. CLASSIFICATION OF RESIDUAL SOLVENTS BY RISK ASSESSMENT, 3. CONTROL STRATEGY, 4. LIMITS OF RESIDUAL SOLVENTS, 5. OPTIONS FOR DESCRIBING LIMITS OF CLASS 2 AND CLASS 3 RESIDUAL SOLVENTS, 6. REPORTING LEVELS OF RESIDUAL SOLVENTS, 7. IDENTIFICATION, CONTROL, AND QUANTIFICATION OF RESIDUAL SOLVENTS, 8. ANALYTICAL PROCEDURES FOR CLASS 1 AND CLASS 2 RESIDUAL SOLVENTS, 9. ANALYTICAL PROCEDURES FOR CLASS 3 RESIDUAL SOLVENTS, APPENDICES, CONTROL STRATEGY, OPTIONS FOR DESCRIBING LIMITS FOR RESIDUAL SOLVENTS, SCREENING FOR WATER-SOLUBLE ARTICLES, PROCEDURE A, PROCEDURE B, SCREENING FOR WATER-INSOLUBLE ARTICLES, CLASS 3 RESIDUAL SOLVENTS, LIMIT TESTS WHEN SOLVENTS LTBP ARE KNOWN, QUANTITATIVE TESTS, QUANTIFICATION FOR WATER-INSOLUBLE ARTICLES, PROCEDURE C, VERIFICATION AND VALIDATION, VERIFICATION OF COMPENDIAL PROCEDURES, VALIDATION OF Revision <467> RESIDUAL SOLVENTS PF 43(2) Pg. ONLINE ALTERNATIVE PROCEDURES Edmond Biba Title, INTRODUCTION/Introduction, PROCEDURE/Sample Preparation, PROCEDURE/qPCR Analysis, ADDITIONAL REQUIREMENTS/USP Reference Standards New <509> RESIDUAL DNA TESTING PF 42(5) Pg. ONLINE <11> Elena Curti TABLE OF CONTENTS, INTRODUCTION, A. DELIVERED-DOSE UNIFORMITYDELIVERED CONTENT UNIFORMITY, B. DROPLET/PARTICLE SIZE DISTRIBUTION-NASAL AEROSOLS, SPRAYS, AND POWDERS DROPLET/PARTICLE SIZE DISTRIBUTION-NASAL AEROSOLS <601> INHALATION AND NASAL DRUG PRODUCTS- AEROSOLS, SPRAYS, AND AND SPRAYS, C. AERODYNAMIC PARTICLE SIZE DISTRIBUTION-INHALATION Revision POWDERS--PERFORMANCE QUALITY TESTS PF 42(6) Pg. ONLINE AEROSOLS, SPRAYS, AND POWDERS Kahkashan Zaidi Revision <660> CONTAINERS -- GLASS PF 43(3) Pg. ONLINE Title, Introduction, SCOPE, DESCRIPTION, SPECIFIC TESTS Desmond Hunt Title, Introduction, 1. INTRODUCTION, 2. SCOPE, 3. ASSESSMENT PROCESS, 4. <665> POLYMERIC COMPONENTS AND SYSTEMS USED IN THE MANUFACTURING OF POLYMERIC MATERIALS OF CONSTRUCTION, 5. POLYMERIC COMPONENTS AND New PHARMACEUTICAL AND BIOPHARMACEUTICAL DRUG PRODUCTS PF 43(3) Pg. ONLINE SYSTEMS Desmond Hunt 2. QUALIFICATION OF NIR SPECTROMETERS, 3. PROCEDURE, 4. VALIDATION AND VERIFICATION, 1. INTRODUCTION, 2. QUALIFICATION OF NIR SPECTROMETERS, USP New <856> NEAR-INFRARED SPECTROSCOPY PF 42(2) Pg. ONLINE REFERENCE STANDARDS <11> Kahkashan Zaidi Introduction, QUALIFICATION OF RAMAN SPECTROMETERS, VALIDATION AND New <858> RAMAN SPECTROSCOPY PF 42(2) Pg. ONLINE VERIFICATION, Title, Introduction, PROCEDURE, VERIFICATION Kahkashan Zaidi <915> MEASUREMENT OF STRUCTURAL STRENGTH OF SEMISOLIDS BY New PENETROMETRY PF 43(2) Pg. ONLINE Title, INTRODUCTION, PROCEDURE, GLOSSARY Antonio Hernandez-Cardoso Title, BACKGROUND, BIOAVAILABILITY, BIOEQUIVALENCE, AND DISSOLUTION, <1090> ASSESSMENT OF DRUG PRODUCT PERFORMANCE--BIOAVAILABILITY, BIOEQUIVALENCE, DISSOLUTION AND IN VITRO PRODUCT PERFORMANCE, Revision BIOEQUIVALENCE, AND DISSOLUTION PF 42(4) Pg. ONLINE BIOWAIVER, APPENDIX William Brown INTRODUCTION, INSTRUMENTATION, METHOD VALIDATION, GLOSSARY, *No Head*, 1. THEORY, 2. TRANSMISSION, REFLECTION, AND TRANSFLECTION MODES, 3. FACTORS THAT AFFECT NIR SPECTRA, 4. PRETREATMENT OF NIR SPECTRAL DATA, 5. INSTRUMENTATION, 6. APPLICATIONS, 7. PROCEDURE VALIDATION, 8. APPENDIX: Revision <1119> NEAR-INFRARED SPECTROSCOPY PF 41(1) Pg. ONLINE GLOSSARY Kahkashan Zaidi Title, Introduction, 1. INTRODUCTION, 2. PERSONNEL TRAINING, 3. BUILDINGS AND FACILITIES, 4. EQUIPMENT AND COMPONENTS, 5. STANDARD OPERATING PROCEDURES, 6. PREPARATION ACTIVITIES, 7. RELEASE OF INVESTIGATIONAL AGENT/PREPARATION, 8. LABELING, 9. ESTABLISHING BEYOND-USE DATES, 10. <1168> COMPOUNDING FOR PHASE I INVESTIGATIONAL STUDIES PF 43(3) Pg. QUALITY ASSURANCE AND QUALITY CONTROL, 11. STORAGE, HANDLING, PACKAGING, New ONLINE AND TRANSPORT, 12. DOCUMENTATION, APPENDIX Jeanne Sun Title, INTRODUCTION, BACKGROUND, EXPERIMENTAL METHODS, SOLUBILITY New <1236> SOLUBILITY MEASUREMENTS PF 43(2) Pg. ONLINE MEASUREMENTS IN BIO-RELEVANT MEDIA, GLOSSARY, REFERENCES Antonio Hernandez-Cardoso Title, Introduction, 1. INTRODUCTION, 2. SCOPE, 3. DESCRIPTION OF ELASTOMERIC COMPONENTS IN PACKAGING SYSTEMS, 4. ELASTOMERIC COMPONENTS-MATERIALS <1381> ELASTOMERIC EVALUATION OF ELASTOMERIC COMPONENTS USED IN OF CONSTRUCTION, 5. ELASTOMERIC COMPONENTS-MANUFACTURING TECHNOLOGY New PHARMACEUTICAL PACKAGING/DELIVERY SYSTEMS PF 43(3) Pg. ONLINE AND STERILIZATION PROCEDURES, 6. TEST PROCEDURES Desmond Hunt Title, 1. INTRODUCTION, 2. EARLY PACKAGE DEVELOPMENT: CLOSURE <1382> ASSESSMENT OF ELASTOMERIC CLOSURE FUNCTIONALITY IN INJECTABLE FUNCTIONALITY ASSESSMENT, 3. ASSESSMENT OF THE FITNESS OF FUNCTIONALITY New PHARMACEUTICAL PACKAGING/DELIVERY SYSTEMS PF 43(3) Pg. ONLINE TEST FOR ITS INTENDED USE, 4. CONCLUSION Desmond Hunt <1467> RESIDUAL SOLVENTS- VERIFICATION OF COMPENDIAL PROCEDURES AND Title, Introduction, VERIFICATION OF COMPENDIAL PROCEDURES, VALIDATION OF New VALIDATION OF ALTERNATIVE PROCEDURES PF 43(2) Pg. ONLINE ALTERNATIVE PROCEDURES Edmond Biba Title, Introduction, PURPOSEINTRODUCTION, SCOPE, GLASS TYPES, FORMATION AND PROCESSINGOF MOLDED AND TUBULAR GLASS CONTAINERS, GLASS CONTAINER SOURCING, GLASS SURFACE CHEMISTRY, FACTORS THAT INFLUENCE INNER SURFACE <1660> EVALUATION OF THE INNER SURFACE DURABILITY OF GLASS CONTAINERS PF DURABILITY, EVALUATION OF THE INNER SURFACE DURABILITY, Revision 43(3) Pg. ONLINE CONCLUSIONSSUMMARY Desmond Hunt <1665> PLASTIC COMPONENTS AND SYSTEMS USED TO MANUFACTURE Title, 1. INTRODUCTION, 2. SCOPE, 3. GENERAL PRINCIPLES, 4. CHARACTERIZATION New PHARMACEUTICAL DRUG PRODUCTS PF 43(3) Pg. ONLINE PROCESS, 5. SAFETY QUALIFICATION, GLOSSARY Desmond Hunt Title, INTRODUCTION, QUALITATIVE AND QUANTITATIVE RAMAN MEASUREMENTS, FACTORS AFFECTING QUANTIFICATION, APPARATUS, QUALIFICATION AND VERIFICATION OF RAMAN SPECTROMETERS, METHOD VALIDATION, DEFINITION OF TERMS AND SYMBOLS, THEORY, SAMPLING FACTORS, SPECIALIZED TECHNIQUES, CALIBRATION, FACTORS THAT AFFECT MEASUREMENT PERFORMANCE, PROCEDURE Revision <1858> RAMAN SPECTROSCOPY - THEORY AND PRACTICE PF 40(6) Pg. ONLINE VALIDATION Kahkashan Zaidi New <1912> MEASUREMENT OF HARDNESS OF SEMISOLIDS PF 43(2) Pg. ONLINE Title, BACKGROUND, EXPERIMENTAL METHODS, GLOSSARY, REFERENCES Antonio Hernandez-Cardoso Title, DEFINITION/Introduction, IDENTIFICATION/A. Infrared Absorption <197K>, IDENTIFICATION/B., ASSAY/Procedure, PERFORMANCE TESTS/Dissolution <711>, PERFORMANCE TESTS/Uniformity of Dosage Units <905>, IMPURITIES/Limit of Acamprosate Related Compound A, IMPURITIES/Organic Impurities, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Acamprosate Calcium RS, ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Acamprosate Related Compound A RS, ADDITIONAL REQUIREMENTS/USP Reference Standards <11>/USP Acamprosate Related Compound New ACAMPROSATE DELAYED-RELEASE TABLETS PF 41(6) Pg. ONLINE B RS Heather Joyce IDENTIFICATION/B. Thin-Layer Chromatographic Identification Test <201>, Revision ACETAMINOPHEN TABLETS PF 42(3) Pg. ONLINE IDENTIFICATION/B., ASSAY/Procedure Clydewyn Anthony DEFINITION/Introduction, IDENTIFICATION/A., IDENTIFICATION/B., ASSAY/Procedure, PERFORMANCE TESTS/Uniformity of Dosage Units <905>, PERFORMANCE TESTS/Deliverable Volume <698>, IMPURITIES/4-Aminophenol in Acetaminophen-
Load more

Recommended publications
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Supporting Information a Analysed Substances
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 List of contents: Tab. A1 Detailed list and classification of analysed substances. Tab. A2 List of selected MS/MS parameters for the analytes. Tab. A1 Detailed list and classification of analysed substances. drug of therapeutic doping agent analytical standard substance abuse drug (WADA class)* supplier (+\-)-amphetamine ✓ ✓ S6 stimulants LGC (+\-)-methamphetamine ✓ S6 stimulants LGC (+\-)-3,4-methylenedioxymethamphetamine (MDMA) ✓ S6 stimulants LGC methylhexanamine (4-methylhexan-2-amine, DMAA) S6 stimulants Sigma cocaine ✓ ✓ S6 stimulants LGC methylphenidate ✓ ✓ S6 stimulants LGC nikethamide (N,N-diethylnicotinamide) ✓ S6 stimulants Aldrich strychnine S6 stimulants Sigma (-)-Δ9-tetrahydrocannabinol (THC) ✓ ✓ S8 cannabinoids LGC (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) S8 cannabinoids LGC morphine ✓ ✓ S7 narcotics LGC heroin (diacetylmorphine) ✓ ✓ S7 narcotics LGC hydrocodone ✓ ✓ Cerillant® oxycodone ✓ ✓ S7 narcotics LGC (+\-)-methadone ✓ ✓ S7 narcotics Cerillant® buprenorphine ✓ ✓ S7 narcotics Cerillant® fentanyl ✓ ✓ S7 narcotics LGC ketamine ✓ ✓ LGC phencyclidine (PCP) ✓ S0 non-approved substances LGC lysergic acid diethylamide (LSD) ✓ S0 non-approved substances LGC psilocybin ✓ S0 non-approved substances Cerillant® alprazolam ✓ ✓ LGC clonazepam ✓ ✓ Cerillant® flunitrazepam ✓ ✓ LGC zolpidem ✓ ✓ LGC VETRANAL™ boldenone (Δ1-testosterone / 1-dehydrotestosterone) ✓ S1 anabolic agents (Sigma-Aldrich)
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Drugs-Biologicals FORMULARY for INTERNET PAGE 12 26 18
    AVG ITEM Average Patient Item Charge Code Description BIL AWP /pkg COST Price 25000041 SODIUM and POTASSIUM BICARBONATE TBEF UD $3.61 $0.12 $1.00 25000054 GLIMEPIRIDE TAB 1 MG UD $8.25 $0.11 $1.30 25000086 amLODIPine TAB 5 MG UD $8.65 $0.06 $1.00 25000087 AMMONIA AROMATIC SOLN 15 % (W/V) UD $3.53 $0.17 $1.00 25000090 AMOXICILLIN CAP 500 MG UD $20.12 $0.19 $1.00 25000102 ABACAVIR TAB 300 MG UD $507.10 $8.45 $16.90 25000103 ACAMPROSATE TBEC 333 MG UD $182.38 $0.80 $1.76 25000104 ACARBOSE TAB 25 MG UD $16.70 $0.27 $1.00 25000106 ACETAMINOPHEN SUPP 120 MG UD $5.09 $0.42 $1.00 25000108 ACETAMINOPHEN SUPP 325 MG UD $4.91 $0.44 $1.00 25000109 ACETAMINOPHEN TAB 325 MG UD $12.39 $0.02 $1.00 25000111 ACETAMINOPHEN TAB 500 MG UD $2.34 $0.02 $1.00 25000112 ACETAMINOPHEN SUPP 650 MG UD $3.83 $0.17 $1.00 25000113 ACETAMINOPHEN SOLN 650 MG/20.3 ML UD $75.74 $0.48 $1.22 25000117 ACETAMINOPHEN-CODEINE TAB 300-30 MG UD $12.41 $0.09 $1.00 25000121 ACETYLCYSTEINE SOLN 200 MG/ML (20 %) UD $18.18 $7.66 $15.32 25000140 ALBUTEROL SULFATE NEBU 2.5MG/3ML (0.083 %) UD $8.58 $0.29 $1.00 25000147 ALLOPURINOL TAB 100 MG UD $18.45 $0.12 $1.00 25000150 ALPRAZolam TAB 0.25 MG UD $8.87 $0.09 $1.00 25000151 ALPRAZolam TAB 0.5 MG UD $4.16 $0.04 $1.00 25000182 AMIODARONE TAB 200 MG UD $15.70 $0.20 $1.00 25000184 AMITRIPTYLINE TAB 10 MG UD $8.73 $0.06 $1.00 25000186 AMITRIPTYLINE TAB 25 MG UD $17.46 $0.08 $1.00 25000188 AMITRIPTYLINE TAB 50 MG UD $34.90 $0.16 $1.00 25000205 HYDROCORTISONE ACETATE SUPP 25 MG UD $127.30 $5.75 $11.50 25000206 HEMORRHOIDAL SUPPOSITORY SUPP 0.25
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61L 27/58 (2006.01) A61L 27/52 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/028622 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 14 March 2014 (14.03.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/785,477 14 March 2013 (14.03.2013) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: MEDICUS BIOSCIENCES LLC [US/US]; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 2528 Qume Dr., Unit #1, San Jose, CA 95 13 1 (US).
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Reference ID: 3940505 FULL PRESCRIBING INFORMATION
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Do not co-administer aliskiren with BYVALSON in patients with These highlights do not include all the information needed to use diabetes. (4) BYVALSON safely and effectively. See full prescribing information for -----------------------WARNINGS AND PRECAUTIONS-----------------------­ BYVALSON. • Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. (5.3) BYVALSON (nebivolol and valsartan) tablets, for oral use • Diabetes: Monitor glucose as β-blockers may mask symptoms of Initial U.S. Approval: 2016 hypoglycemia. (5.7) • Monitor renal function and potassium in susceptible patients. (5.11) WARNING: FETAL TOXICITY ------------------------------ADVERSE REACTIONS------------------------------­ See full prescribing information for complete boxed warning. No adverse reactions were observed more frequently on BYVALSON than on • When pregnancy is detected, discontinue BYVALSON as soon as placebo. (6.1) possible (5.1, 8.1) • Drugs, including BYVALSON, that act directly on the renin­ To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1­ angiotensin system can cause injury and death to the developing 800-272-5525or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. fetus. (5.1, 8.1) ------------------------------DRUG INTERACTIONS------------------------------­ • CYP2D6 enzyme inhibitors increase nebivolol levels. (7) ----------------------------INDICATIONS AND USAGE--------------------------­ • Reserpine or clonidine may produce excessive reduction of sympathetic BYVALSON is a beta adrenergic blocker and an angiotensin II receptor activity. (7) blocker (ARB) indicated for the treatment of hypertension, to lower blood • Digitalis glycosides increase the risk of bradycardia. (7) pressure. Lowering blood pressure reduces the risk of fatal and nonfatal • Verapamil- or diltiazem-type calcium channel blockers may cause cardiovascular events, primarily strokes and myocardial infarctions.
    [Show full text]
  • 3258 N:O 1179
    3258 N:o 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
    [Show full text]
  • Comparative Effects of Nebivolol and Atenolol on Blood Pressure and Insulin Sensitivity in Hypertensive Subjects with Type II Diabetes
    Journal of Human Hypertension (1997) 11, 753–757 1997 Stockton Press. All rights reserved 0950-9240/97 $12.00 ORIGINAL ARTICLE Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes R Fogari1, A Zoppi1, P Lazzari1, A Mugellini1, P Lusardi1, P Preti1, L Van Nueten2 and C Vertommen2 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; 2Janssen Research Foundation, Beerse, Belgium The aim of this double-blind, parallel group study was to rate during the last 60 min of clamp and total glucose compare the effects of nebivolol and atenolol on blood requirements were evaluated. Nebivolol 5 mg once daily pressure (BP) and insulin sensitivity in hypertensive was of an equivalent efficacy as atenolol 50 mg once patients with type II, non-insulin dependent diabetes daily at reducing supine and standing systolic and dias- mellitus (NIDDM). After a 4-week run-in period on pla- tolic BP values. Neither b-blocker adversely affected cebo, 30 patients (14 males and 16 females) aged 43 to carbohydrate metabolism in terms of insulin sensitivity, 69 years, with stable NIDDM and mild to moderate whole body glucose utilization, HbA1c and 24-h urinary hypertension (DBP >95 and ,116 mm Hg) were random- C-peptide excretion. No significant changes in choles- ised to receive either nebivolol 5 mg or atenolol 50 mg, terol (total, high density and low density lipoprotein) both administered once daily for 6 months. At the end and triglycerides plasma levels were observed with both of the placebo and the active treatment periods, supine b-blockers.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]